Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bristol-Myers Squibb Co. (BMY) PT Lowered to $47 at BMO Capital; See Much Uncertainty and Increased Risk
January 23, 2017 1:46 PM ESTBMO Capital analyst Alex Arfaei lowered his price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $47.00 (from $53.00) while maintaining a Market Perform rating. The firm still sees much uncertainty and Increased execution risk and thinks a takeout/merger is less likely.
Arfaei commented,... More
Cowen Downgrades Bristol-Myers Squibb Co. (BMY) to Market Perform
January 20, 2017 7:44 AM ESTCowen downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $55.49 yesterday.
... More